Plasma 25-Hydroxyvitamin D and Mortality in Patients With Suspected Stable Angina Pectoris

Context and Objective Vitamin D status may affect cardiovascular disease (CVD) development and survival. We studied the relationship between concentrations of the circulating biomarker 25-hydroxyvitamin D (25OHD) and all-cause and cardiovascular mortality risk. Design, Setting, Participants, and Main Outcome Measures 25OHD, the sum of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2, was analyzed in plasma samples from 4114 white patients suspected of having stable angina pectoris and was adjusted for seasonal variation. Hazard ratios (HRs) for all-cause and cardiovascular mortality were estimated by using multivariable Cox models with 25OHD as the main exposure variable, with adjustment for study site, age, sex, smoking, body mass index, estimated glomerular filtration rate, and systolic blood pressure. Results A total of 895 (21.8%) deaths, including 407 (9.9%) from CVD causes, occurred during a mean ± standard deviation follow-up of 11.9 ± 3.0 years. Compared with the first 25OHD quartile, HRs in the second, third, and fourth quartiles were 0.64 [95% confidence interval (CI), 0.54 to 0.77], 0.56 (95% CI, 0.46 to 0.67), and 0.56 (95% CI, 0.46 to 0.67) for all-cause mortality and 0.70 (95% CI, 0.53 to 0.91), 0.60 (95% CI, 0.45 to 0.79), and 0.57 (95% CI, 0.43 to 0.75) for cardiovascular mortality, respectively. Threshold analysis demonstrated increased all-cause and CVD mortality in patients with 25OHD concentrations below ∼42.5 nmol/L. Moreover, analysis suggested increased all-cause mortality at concentrations >100 nmol/L. Conclusion Plasma 25OHD concentrations were inversely associated with cardiovascular mortality and nonlinearly (U-shaped) associated with all-cause mortality.

[1]  J. Gummert,et al.  Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily , 2017, European heart journal.

[2]  Stephen Burgess,et al.  Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction , 2017, JAMA.

[3]  Kay-Tee Khaw,et al.  Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study: A Randomized Clinical Trial , 2017, JAMA cardiology.

[4]  Yilong Wang,et al.  Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response meta-analysis of prospective studies. , 2017, The American journal of clinical nutrition.

[5]  Vilmundur Gudnason,et al.  Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium , 2017, PloS one.

[6]  M. Mazidi,et al.  Effect of statins on serum vitamin D concentrations: a systematic review and meta‐analysis , 2017, European journal of clinical investigation.

[7]  S. Pilz,et al.  Effect of Two Different Multimicronutrient Supplements on Vitamin D Status in Women of Childbearing Age: A Randomized Trial , 2017, Nutrients.

[8]  J. Brent Richards,et al.  Mendelian Randomization Studies Do Not Support a Role for Vitamin D in Coronary Artery Disease , 2016, Circulation. Cardiovascular genetics.

[9]  H. Suryapranata,et al.  Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. , 2016, Thrombosis research.

[10]  P. Ueland,et al.  Cosinor modelling of seasonal variation in 25-hydroxyvitamin D concentrations in cardiovascular patients in Norway , 2015, European Journal of Clinical Nutrition.

[11]  P. Ueland,et al.  Vitamin D status was not associated with ‘one-year’ progression of coronary artery disease, assessed by coronary angiography in statin-treated patients , 2015, European journal of preventive cardiology.

[12]  Shoaib Afzal,et al.  No evidence that genetically reduced 25-hydroxyvitamin D is associated with increased risk of ischaemic heart disease or myocardial infarction: a Mendelian randomization study. , 2015, International journal of epidemiology.

[13]  Min‐ge Xie,et al.  Temporal Relationship between Vitamin D Status and Parathyroid Hormone in the United States , 2015, PloS one.

[14]  A. Tjønneland,et al.  A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. , 2015, The Journal of clinical endocrinology and metabolism.

[15]  W. Rathmann,et al.  Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States , 2014, BMJ : British Medical Journal.

[16]  M. Whooley,et al.  Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. , 2014, American journal of epidemiology.

[17]  I. Reid,et al.  The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. , 2014, The lancet. Diabetes & endocrinology.

[18]  R. Kumar,et al.  A lifetime of hypercalcemia and hypercalciuria, finally explained. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  H. Meyer,et al.  Vitamin D – a systematic literature review for the 5th edition of the Nordic Nutrition Recommendations , 2013, Food & nutrition research.

[20]  P. Ueland,et al.  Plasma Dimethylglycine and Risk of Incident Acute Myocardial Infarction in Patients With Stable Angina Pectoris , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[21]  H. Boeing,et al.  Plasma 25-Hydroxyvitamin D and Its Genetic Determinants in Relation to Incident Myocardial Infarction and Stroke in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany Study , 2013, PloS one.

[22]  J. Gummert,et al.  Vitamin D status and the risk of major adverse cardiac and cerebrovascular events in cardiac surgery. , 2013, European heart journal.

[23]  W. März,et al.  Vitamin D and mortality: a Mendelian randomization study. , 2013, Clinical chemistry.

[24]  M. Hoshen,et al.  Vitamin D levels for preventing acute coronary syndrome and mortality: evidence of a nonlinear association. , 2013, The Journal of clinical endocrinology and metabolism.

[25]  J. Manson,et al.  Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Studies , 2012, Circulation. Cardiovascular quality and outcomes.

[26]  Alex J. Brown,et al.  Bioavailable vitamin D in chronic kidney disease. , 2012, Kidney international.

[27]  J. Christensen,et al.  A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. , 2012, The Journal of clinical endocrinology and metabolism.

[28]  B. Kestenbaum,et al.  Serum 25-Hydroxyvitamin D Concentration and Risk for Major Clinical Disease Events in a Community-Based Population of Older Adults , 2012, Annals of Internal Medicine.

[29]  J. Mæhlen,et al.  The value of autopsies for determining the cause of death. , 2012, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[30]  P. Ueland,et al.  Determination of vitamins A, D and E in a small volume of human plasma by a high-throughput method based on liquid chromatography/tandem mass spectrometry. , 2011, Rapid communications in mass spectrometry : RCM.

[31]  H. Brenner,et al.  Serum vitamin D and risk of secondary cardiovascular disease events in patients with stable coronary heart disease. , 2010, American heart journal.

[32]  P. Ueland,et al.  Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[33]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[34]  S. Vollset,et al.  Angiography : A Randomized Controlled Trial CoronaryWith Homocysteine-Lowering B Vitamins After Mortality and Cardiovascular Events in Patients Treated , 2008 .

[35]  K. Cao,et al.  Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. , 2008, Kidney international.

[36]  Stefan Pilz,et al.  Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. , 2008, Archives of internal medicine.

[37]  C. Mathieu,et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. , 2008, Endocrine reviews.

[38]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .

[39]  A. K. Jarvis,et al.  1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. , 1997, The American journal of physiology.

[40]  R. Morris,et al.  1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. , 1991, The Journal of clinical investigation.

[41]  R. Simpson,et al.  Vitamin D3 and cardiovascular function in rats. , 1987, The Journal of clinical investigation.

[42]  C. Glueck,et al.  Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation. , 2017, Atherosclerosis.

[43]  P. Thompson,et al.  Low vitamin D does not predict statin associated muscle symptoms but is associated with transient increases in muscle damage and pain. , 2017, Atherosclerosis.

[44]  D. Talwar,et al.  Quantitative data on the magnitude of the systemic inflammatory response and its effect on micronutrient status based on plasma measurements. , 2012, The American journal of clinical nutrition.

[45]  Sumithra J. Mandrekar,et al.  Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes , 2006 .